General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Bayer(MODEST), AstraZeneca Pharmaceuticals(SIGNIFICANT), Novartis(SIGNIFICANT), Merck(MODEST), Ionis(MODEST), Pfizer(MODEST), Lilly Medical (MODEST), Amgen(MODEST), Bristol-Myers Squibb Company (MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Cyclerion(MODEST), Cytokinetics (MODEST), GSK(MODEST), Imara(MODEST), MyoKardia(MODEST), Regeneron(MODEST), Shifamed(MODEST), United Therapeutics (MODEST), Boston Scientific (MODEST), Abbott (MODEST), CVRx(MODEST), Prothena(MODEST), Tenax(MODEST), Edwards Lifesciences(MODEST), Intellia(MODEST), Secretome(NONE), Rivus(MODEST), Sardocor(MODEST), BaroPace(MODEST), Axon(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: National Institutes of Health(SIGNIFICANT), Actelion(SIGNIFICANT), American Heart Association(SIGNIFICANT), Corvia(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Pfizer Inc(SIGNIFICANT)
